April 22, 2015

Source: Crop Biotech Update

The golden mosaic virus disease is considered as one of the most important diseases that limit bean production in Latin America.In 2011, the transgenic bean event Embrapa 5.1,  with resistance to bean golden mosaic virus was approved for commercial release in Brazil.

A team led by Francisco Aragão, from Embrapa Recursos Genéticos e Biotecnologia in Brazil, evaluated the nutritional components of the beans in the primary transgenic line as well as  lines derived from crosses and backcrosses of the transgenic with two commercial cultivars.

Results revealed that the transgenic bean event was nutritionally equivalent to the non-transgenic bean plants. Moreover, the amounts of the nutritional components are within the range of values observed for several bean commercial varieties grown.

To learn more, read the full article on Springer Link.

Comparative analysis of nutritional compositions of transgenic RNAi-mediated virus-resistant bean (event EMB-PV051-1) with its non-transgenic counterpart

Website: http://www.isaaa.org/kc/

Published: April 22, 2015